171 related articles for article (PubMed ID: 32567031)
1. Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2.
Morimoto Y; Takada K; Takeuchi O; Watanabe K; Hirohara M; Hamamoto T; Masuda Y
Mol Cell Biochem; 2020 Sep; 472(1-2):187-198. PubMed ID: 32567031
[TBL] [Abstract][Full Text] [Related]
2. Prexasertib increases the sensitivity of pancreatic cancer cells to gemcitabine and S‑1.
Morimoto Y; Takada K; Takeuchi O; Takagi A; Watanabe K; Hirohara M; Hamamoto T; Masuda Y
Oncol Rep; 2020 Feb; 43(2):689-699. PubMed ID: 31789403
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous inhibition of Chk1 and Bcl-xL induces apoptosis
Morimoto Y; Takada K; Takeuchi O; Watanabe K; Hirohara M; Masuda Y
J Chemother; 2023 Sep; 35(5):435-447. PubMed ID: 36134604
[TBL] [Abstract][Full Text] [Related]
4. Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL.
Shi J; Zhou Y; Huang HC; Mitchison TJ
Cancer Res; 2011 Jul; 71(13):4518-26. PubMed ID: 21546570
[TBL] [Abstract][Full Text] [Related]
5. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
6. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP
Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649
[TBL] [Abstract][Full Text] [Related]
7. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
Phillips DC; Xiao Y; Lam LT; Litvinovich E; Roberts-Rapp L; Souers AJ; Leverson JD
Blood Cancer J; 2015 Nov; 5(11):e368. PubMed ID: 26565405
[TBL] [Abstract][Full Text] [Related]
8. CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax.
Kour S; Rana S; Contreras JI; King HM; Robb CM; Sonawane YA; Bendjennat M; Crawford AJ; Barger CJ; Kizhake S; Luo X; Hollingsworth MA; Natarajan A
Mol Pharmacol; 2019 Oct; 96(4):419-429. PubMed ID: 31467029
[TBL] [Abstract][Full Text] [Related]
9. PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer.
Khan S; Cao L; Wiegand J; Zhang P; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
Cells; 2024 Mar; 13(6):. PubMed ID: 38534371
[TBL] [Abstract][Full Text] [Related]
10. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.
Leverson JD; Phillips DC; Mitten MJ; Boghaert ER; Diaz D; Tahir SK; Belmont LD; Nimmer P; Xiao Y; Ma XM; Lowes KN; Kovar P; Chen J; Jin S; Smith M; Xue J; Zhang H; Oleksijew A; Magoc TJ; Vaidya KS; Albert DH; Tarrant JM; La N; Wang L; Tao ZF; Wendt MD; Sampath D; Rosenberg SH; Tse C; Huang DC; Fairbrother WJ; Elmore SW; Souers AJ
Sci Transl Med; 2015 Mar; 7(279):279ra40. PubMed ID: 25787766
[TBL] [Abstract][Full Text] [Related]
11. Nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL, (-)-Gossypol, enhances biological effect of genistein against BxPC-3 human pancreatic cancer cell line.
Mohammad RM; Wang S; Banerjee S; Wu X; Chen J; Sarkar FH
Pancreas; 2005 Nov; 31(4):317-24. PubMed ID: 16258364
[TBL] [Abstract][Full Text] [Related]
12. Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer.
Zoeller JJ; Vagodny A; Daniels VW; Taneja K; Tan BY; DeRose YS; Fujita M; Welm AL; Letai A; Leverson JD; Blot V; Bronson RT; Dillon DA; Brugge JS
Breast Cancer Res; 2020 Nov; 22(1):132. PubMed ID: 33256808
[TBL] [Abstract][Full Text] [Related]
13. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
[TBL] [Abstract][Full Text] [Related]
14. Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models.
Tan N; Wong M; Nannini MA; Hong R; Lee LB; Price S; Williams K; Savy PP; Yue P; Sampath D; Settleman J; Fairbrother WJ; Belmont LD
Mol Cancer Ther; 2013 Jun; 12(6):853-64. PubMed ID: 23475955
[TBL] [Abstract][Full Text] [Related]
15. Hydroxychloroquine Promotes Bcl-xL Inhibition-induced Apoptosis in BxPC-3 Human Pancreatic Cancer Cells.
Hoque MM; Iida Y; Kotani H; Kartika ID; Harada M
Anticancer Res; 2022 Jul; 42(7):3495-3506. PubMed ID: 35790256
[TBL] [Abstract][Full Text] [Related]
16. Focal adhesion kinase inhibitor PF573228 and death receptor 5 agonist lexatumumab synergistically induce apoptosis in pancreatic carcinoma.
Zhao X; Sun W; Puszyk WM; Wallet S; Hochwald S; Robertson K; Liu C
Tumour Biol; 2017 May; 39(5):1010428317699120. PubMed ID: 28459212
[TBL] [Abstract][Full Text] [Related]
17. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
[TBL] [Abstract][Full Text] [Related]
18. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo.
Chen J; Jin S; Abraham V; Huang X; Liu B; Mitten MJ; Nimmer P; Lin X; Smith M; Shen Y; Shoemaker AR; Tahir SK; Zhang H; Ackler SL; Rosenberg SH; Maecker H; Sampath D; Leverson JD; Tse C; Elmore SW
Mol Cancer Ther; 2011 Dec; 10(12):2340-9. PubMed ID: 21914853
[TBL] [Abstract][Full Text] [Related]
19. Combination Treatment with the BRAF
Jeong JH; Oh JM; Jeong SY; Lee SW; Lee J; Ahn BC
Thyroid; 2019 Apr; 29(4):540-548. PubMed ID: 30869573
[TBL] [Abstract][Full Text] [Related]
20. Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma.
Tanos R; Karmali D; Nalluri S; Goldsmith KC
BMC Cancer; 2016 Feb; 16():97. PubMed ID: 26874859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
